Patents Assigned to ImmuLogix Ltd
  • Composition of tumor-associated proliferative peptides and related anti-cancer immunogen for the treatment of lung cancers and other cancers
    Patent number: 11911451
    Abstract: The present invention relates to immunogens directed against lung cancer associated proliferative peptides and growth factors and its uses thereof in conjunction with chemotherapeutics in the early and advanced treatment of various malignant diseases, especially including lung cancers, both small cell lung carcinomas (SCLC), non-small cell lung (NSCLC) cancers and neuroendocrine-type cancers.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: February 27, 2024
    Assignee: ImmuLogix Ltd
    Inventors: Richard Ascione, Shengmei Qi
  • COMPOSITION OF TUMOR-ASSOCIATED PROLIFERATIVE PEPTIDES AND RELATED ANTI-CANCER IMMUNOGEN FOR THE TREATMENT OF LUNG CANCERS AND OTHER CANCERS
    Publication number: 20210121546
    Abstract: The present invention relates to immunogens directed against lung cancer associated proliferative peptides and growth factors and its uses thereof in conjunction with chemotherapeutics in the early and advanced treatment of various malignant diseases, especially including lung cancers, both small cell lung carcinomas (SCLC), non-small cell lung (NSCLC) cancers and neuroendocrine-type cancers.
    Type: Application
    Filed: August 21, 2018
    Publication date: April 29, 2021
    Applicant: ImmuLogix Ltd
    Inventors: Richard ASCIONE, Shengmei QI